VTYX | Ventyx Biosciences, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	2.2101 - 2.3600
52 Week Range	1.6700 - 11.48
Beta	0.37
Implied Volatility	121.46%
IV Rank	59.60%
Day's Volume	480,230
Average Volume	1,394,260
Shares Outstanding	70,710,670
Market Cap	160,513,221
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-10-21

Valuation
Profitability
Growth
Health
P/E Ratio	-0.97
Forward P/E Ratio	N/A
EPS	-2.35
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	75
Country	USA
Website	VTYX

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases which is in phase I clinical trials. In addition, the company develops CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.

VTYX's peers: ACLX, ASND, CLDX, COGT, HRMY, IDYA, IMCR, IVA, KNSA, NUVL, PCVX, PRTA, PTGX, REPL, RVNC, RYTM, SAGE, TECH, TVTX, UTHR, VCYT, VERA, VOR, VRNA, DICE, CERE, GPCR, SNDX, XENE, MLTX, PROK

*Chart delayed

Analyzing fundamentals for VTYX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see VTYX Fundamentals page.

Watching at VTYX technicals we can see that long-term trend is bearish, while middle-term trend is bullish, but short-term trend is bearish. More technicals details can be found on VTYX Technicals page.